Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
NCT05537584Phase 4Completed
- Sponsor
- McLean Hospital
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sertraline and bupropion in major depressive disorder (MDD) (2 arms), sponsored by McLean Hospital. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Sep 2022; status: completed.
02
Drugs
sertralinebupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05537584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537584.